These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 17524039

  • 1. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM, Wagner A, Asia Pacific Gastroenterology Group.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [Abstract] [Full Text] [Related]

  • 2. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 3. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [Abstract] [Full Text] [Related]

  • 4. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD003960. PubMed ID: 17943807
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G, Snape WJ, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA.
    Aliment Pharmacol Ther; 2002 Oct 17; 16(10):1701-8. PubMed ID: 12269961
    [Abstract] [Full Text] [Related]

  • 6. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group.
    Zhonghua Nei Ke Za Zhi; 2003 Feb 17; 42(2):88-90. PubMed ID: 12783702
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR.
    J Am Pharm Assoc (2003); 2004 Feb 17; 44(1):41-51. PubMed ID: 14965152
    [Abstract] [Full Text] [Related]

  • 8. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rüegg P, Jones J, Wagner A.
    Scand J Gastroenterol; 2004 Feb 17; 39(2):119-26. PubMed ID: 15000272
    [Abstract] [Full Text] [Related]

  • 9. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
    Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A.
    Gut; 2003 May 17; 52(5):671-6. PubMed ID: 12692051
    [Abstract] [Full Text] [Related]

  • 10. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD.
    Adv Ther; 2009 May 17; 26(5):519-30. PubMed ID: 19444393
    [Abstract] [Full Text] [Related]

  • 11. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S, Berrada D, Lembo A.
    Expert Opin Pharmacother; 2004 Nov 17; 5(11):2369-79. PubMed ID: 15500384
    [Abstract] [Full Text] [Related]

  • 12. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome.
    Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P, TegaSwiss Study Group.
    Eur J Gastroenterol Hepatol; 2005 Apr 17; 17(4):421-7. PubMed ID: 15756094
    [Abstract] [Full Text] [Related]

  • 13. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 17; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Rüegg P, Lefkowitz M.
    Aliment Pharmacol Ther; 2002 Nov 17; 16(11):1877-88. PubMed ID: 12390096
    [Abstract] [Full Text] [Related]

  • 15. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ, Frampton JE, Croom KF.
    Drugs; 2003 Nov 17; 63(11):1101-20. PubMed ID: 12749744
    [Abstract] [Full Text] [Related]

  • 16. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
    Layer P, Keller J, Mueller-Lissner S, Rüegg P, Loeffler H.
    Digestion; 2005 Nov 17; 71(4):238-44. PubMed ID: 16024929
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, Di Santo R.
    Antiinflamm Antiallergy Agents Med Chem; 2020 Nov 17; 19(4):342-369. PubMed ID: 31518227
    [Abstract] [Full Text] [Related]

  • 19. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug 17; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 20. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK, Ainsworth MA.
    Ugeskr Laeger; 2007 Jun 04; 169(23):2190-2. PubMed ID: 17592683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.